Novo Nordisk Q3 Earnings Preview: Investors to Focus on Wegovy Sales

Mitrade
coverImg
Source: DepositPhotos

Insights – Novo Nordisk (NVO.US) is set to release its Q3 earnings before the market opens on Wednesday, November 6. Investors will focus on the latest supply-demand dynamics and market share of its best-selling weight-loss drugs.


According to FactSet, analysts expect Novo Nordisk’s Q3 net sales to grow 26% year-over-year to $10.57 billion, with earnings per share increasing by 24% to $0.88.


17307991524668


In Q2, net sales rose 25% year-over-year to DKK 68.06 billion (approximately $9.97 billion), slightly falling short of the market's expectation.


However, due to strong demand, Novo Nordisk raised its full-year sales forecast to 22%-28% from 19%-27%. However, it lowered its operating profit growth outlook to 20%-28% from 22%-30% as it expands production capacity.


Growth Potential of the Blockbuster Weight-Loss Drug


The market is closely watching the growth potential of Wegovy (semaglutide), Novo Nordisk's blockbuster weight-loss drug, which has driven the company’s stock price to soar since its launch in June 2021, making Novo Nordisk the largest publicly traded company in Europe by market capitalization.


Analysts expect combined Q3 sales of Wegovy and its sister drug Ozempic to reach approximately $6.8 billion, up from $5.4 billion in Q2. Novo Nordisk CFO Karsten Munk Knudsen stated before that by 2024, weekly Wegovy prescriptions in the U.S. have doubled, rising from 100,000 to 200,000. However, JPMorgan analysts had predicted that Q3 sales of Wegovy would fall short of expectations Previously.


Despite the success of Wegovy and Ozempic, investors are keeping a close eye on competitors in the weight-loss market, as they launch their own drugs. For instance, pharmaceutical giant Eli Lilly & Co (NYSE: LLY) has introduced Zepbound.


As Novo Nordisk releases its latest earnings on Wednesday, a key focus for investors will be how much market share these GLP-1 competitors can capture from Wegovy and Ozempic.


Stock to Rise 25% Over the Next Year?


In September, Novo Nordisk’s stock declined, primarily due to disappointing interim trial data for its "next-generation" weight-loss drug, monlunabant, and a U.S. Senate hearing on Wegovy’s pricing.


Nevertheless, analysts remain optimistic about Novo Nordisk’s future earnings, expecting the stock to rise by 25% over the next year. Wall Street analysts believe the company is taking steps to meet the strong demand for Wegovy and will conduct important clinical trials for its next-generation weight-loss drug this year, which could further boost the stock.


Cantor Fitzgerald reiterated its overweight rating on Novo Nordisk, maintaining a price target of $160. BMO Capital Markets kept its buy rating but lowered the price target from $160 to $156. TD Cowen also maintained its buy rating with a price target of $155.

Read more

  • Gold Hits Near 1.5-Year Low Below $3,800 as Bears Threaten Drop to $3,500
  • Nvidia posts record $115.8B Q3 revenue, but crypto stays muted
  • Australian Dollar declines below 0.6750 after RBA minutes, US Retail Sales data in focus
  • US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC Minutes
  • Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150?
  • Note: If you want to share the article 《Novo Nordisk Q3 Earnings Preview: Investors to Focus on Wegovy Sales》, make sure you retain the original link. For more information, please visit Insights or browse www.mitrade.com.

    * The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

    goTop
    quote
    Related Articles
    placeholder
    Nvidia posts record $115.8B Q3 revenue, but crypto stays mutedThe crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
    Author  FXStreet
    Yesterday 01: 46
    The crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
    placeholder
    Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
    Author  TradingKey
    Nov 17, Tue
    As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
    placeholder
    Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    Author  Irene Q.
    Nov 16, Mon
    The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    placeholder
    Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    Author  Irene Q.
    Nov 16, Mon
    Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    placeholder
    Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
    Author  Irene Q.
    Nov 16, Mon
    Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.

    US Stocks Related Articles

    • 10 Best Day Trading Platforms for Beginners and Active Traders in 2026: A Practical Guide
    • How To Invest in SpaceX Stock in 2026? Everything Investors Need to Know
    • Practice Trading Us Stocks? These Are 10 Best Stock Trading Demo Apps For Beginners
    • ​5 Best Paper Trading Platforms for 2026 (Free Demo Accounts for Beginners & Traders)
    • Wall Street’s Top 10 US Stocks for 2026 vs What Reddit Is Actually Buying
    • Is Mitrade Right for You? A Complete Guide on How to Start Trading CFDs in 5 Steps

    Click to view more